$4.46 Billion is the total value of NEA Management Company, LLC's 58 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
COUR | New | COURSERA INC | $952,060,000 | – | 21,156,891 | +100.0% | 21.37% | – |
MILE | New | METROMILE INC | $96,564,000 | – | 9,384,295 | +100.0% | 2.17% | – |
SVRA | New | SAVARA INC | $50,207,000 | – | 24,137,931 | +100.0% | 1.13% | – |
STSA | New | SATSUMA PHARMACEUTICALS INC | $17,716,000 | – | 2,997,682 | +100.0% | 0.40% | – |
VIRX | New | VIRACTA THERAPEUTICS INC | $343,000 | – | 37,093 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
TREVENA INC | 31 | Q3 2021 | 3.3% |
AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
ARDELYX INC | 29 | Q3 2021 | 11.9% |
RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.